These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes. Godschalk PC; Kuijf ML; Li J; St Michael F; Ang CW; Jacobs BC; Karwaski MF; Brochu D; Moterassed A; Endtz HP; van Belkum A; Gilbert M Infect Immun; 2007 Mar; 75(3):1245-54. PubMed ID: 17261613 [TBL] [Abstract][Full Text] [Related]
7. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Koga M; Takahashi M; Masuda M; Hirata K; Yuki N Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859 [TBL] [Abstract][Full Text] [Related]
8. [The use of intravenous immunglobulin in the treatment of autoimmune neuromuscular diseases]. Molnár MJ Ideggyogy Sz; 2006 Mar; 59(3-4):98-106. PubMed ID: 16634454 [TBL] [Abstract][Full Text] [Related]
9. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Yuki N; Susuki K; Koga M; Nishimoto Y; Odaka M; Hirata K; Taguchi K; Miyatake T; Furukawa K; Kobata T; Yamada M Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11404-9. PubMed ID: 15277677 [TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. Ang CW; De Klerk MA; Endtz HP; Jacobs BC; Laman JD; van der Meché FG; van Doorn PA Infect Immun; 2001 Apr; 69(4):2462-9. PubMed ID: 11254608 [TBL] [Abstract][Full Text] [Related]
11. Antibodies induced by ganglioside-mimicking Campylobacter jejuni lipooligosaccharides recognise epitopes at the nodes of Ranvier. Moran AP; Annuk H; Prendergast MM J Neuroimmunol; 2005 Aug; 165(1-2):179-85. PubMed ID: 15993494 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis. Yuki N Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987 [TBL] [Abstract][Full Text] [Related]
13. [Pathogenesis of axonal Guillain-Barré syndrome]. Yuki N Rinsho Shinkeigaku; 2007 Jan; 47(1):1-7. PubMed ID: 17491330 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. Koga M; Gilbert M; Takahashi M; Li J; Koike S; Hirata K; Yuki N J Infect Dis; 2006 Feb; 193(4):547-55. PubMed ID: 16425134 [TBL] [Abstract][Full Text] [Related]
15. Neuroleptic malignant syndrome and acute motor axonal neuropathy after Campylobacter jejuni infection. Rajabally YA; Ramlackhansingh A; Fraser M; Abbott RJ Neurophysiol Clin; 2009 Aug; 39(3):135-8. PubMed ID: 19716463 [TBL] [Abstract][Full Text] [Related]
16. [Guillain-Barré syndrome]. Koga M; Yuki N Ryoikibetsu Shokogun Shirizu; 2000; (31):35-8. PubMed ID: 11269101 [No Abstract] [Full Text] [Related]
17. [Guillain-barré syndrome associated Campylobacter jejuni serotype Penner 2: a case report]. Watanabe M; Kinoshita I; Hujimoto M; Nakane S; Motomura M; Nakamura T; Kusunoki S; Takahashi M; Saitoh K No To Shinkei; 2001 Aug; 53(8):759-62. PubMed ID: 11577419 [TBL] [Abstract][Full Text] [Related]
18. Brucella melitensis infection associated with Guillain-Barré syndrome through molecular mimicry of host structures. Watanabe K; Kim S; Nishiguchi M; Suzuki H; Watarai M FEMS Immunol Med Microbiol; 2005 Aug; 45(2):121-7. PubMed ID: 16051063 [TBL] [Abstract][Full Text] [Related]
20. [A patient with Guillain-Barré syndrome in association with Campylobacter jejuni enteritis (PEN19:LIO7) in a patient with HLA-B52 antigen]. Kaida K; Yuki N; Takahashi M; Kamakura K; Nagata N Rinsho Shinkeigaku; 1994 Jul; 34(7):733-5. PubMed ID: 7955736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]